NEJM publishes RVMD Phase 1/2 data on RASONQUE in metastatic NSCLC
NEJM published Phase 1/2 clinical data on Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.